<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 14, Issue 04 , 2022 </Volume-Issue>
      <Season>October-December </Season>
      <ArticleTitle>Nanocarrier based drug delivery system – Future of Alzheimer disease</ArticleTitle>
      <Abstract>Alzheimer’s disease (AD) has risen to the top most cause of mortality in the world. Every twenty years, the illness rate doubles, affecting about one in every 10 households. AD is characterized by a gradual loss of neurons in the cerebral cortex, resulting in brain shrinkage. Senile neuritic plaques and neurofibrillary tangles become the disease’s primary characteristic. However, a continuous strategy is customized to cure AD effectively. However, as a result of difficulties in the medication delivery system induced by different barriers such as blood–brain barrier and cerebrospinal fluid has become the primary cause of therapeutic failure. Thus, to address these problems, nanotechnology is a potential technique for overcoming them. This study discusses the use of targeted delivery of medicament for the successful remedy and diagnosis of AD that utilizes nanocarriers as an alternative administration route, thus allowing the release of the drug intocentral nervous system.</Abstract>
      <Keywords>Dementia, Alzheimer’s disease, Nanocarriers, Blood brain barrier, Targeted drug delivery</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14356&amp;title=Nanocarrier based drug delivery system – Future of Alzheimer disease</Abstract>
        <References>1. World Health Organization. Neurological Disorders: Public Health Challenges. Geneva: World Health Organization; 2006.&#13;
2. Yang HD, Kim DH, Lee SB, Young LD. History of Alzheimer’s disease. Dement Neurocogn Disord 2016;15:115-21.&#13;
3. Duong S, Patel T, Chang F. Dementia: What pharmacists need to know. Can Pharm J (Ott) 2017;150:118-29.&#13;
4. Dementia. Available from: https://www.who.int/newsroom/fact-sheets/detail/dementia [Last accesed on 2022].&#13;
5. Alzheimer’s Disease Fact Sheet. National Institute on Aging. Available from: https://www.nia.nih.gov/health/ alzheimers-disease-fact-sheet [Last accessed on 2021].&#13;
6. Bondi MW, Edmonds EC, Salmon DP. Alzheimer’s disease: Past, present, and future. J Int Neuropsychol Soc 2017;23:818-31&#13;
7. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009;11:111-28.&#13;
8. Ganguli M, Ratcliff G, Chandra V, Sharma S, Gilby J, Pandav R, et al. A hindi version of the MMSE: The development of a cognitive screening instrument for a largely illiterate rural elderly population in India. Int J Geriatr Psychiatry 1995;10:367-77.&#13;
9. Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C. Early-onset Alzheimer’s disease: What is missing in research? Curr Neurol Neurosci Rep 2021;21:4.&#13;
10. Mudigonda K. Harsh Mohan Pathology Practical Book. 2nd ed. New Dehli: Jaypee Publisher; 2007;160-4.&#13;
11. Sanabria-Castro A, Alvarado-Echeverrand;iacute;a I, MongeBonilla C. Molecular pathogenesis of Alzheimer’s disease: An update. Ann Neurosci 2017;24:46-54.&#13;
12. Chen G, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: Structure, biology and structurebased therapeutic development. Acta Pharmacol Sin 2017;38:1205-35.&#13;
13. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 2019;14:32.&#13;
14. Lanoiseland;eacute;e HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med 2017;14:e1002270.&#13;
15. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 2019;14:5541-54.&#13;
16. How is Alzheimer’s Disease Treated? National Institute on Aging. Available from: https://www.nia.nih.gov/health/ how-alzheimers-disease-treated [Last accessed on 2021].&#13;
17. FDA Center for Drug Evaluation and Research. FDA’s Decision to Approve New Treatment for Alzheimer’s Disease. United States: Food and Drug Administration; 2021.&#13;
18. Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Deliv 2018;25:307-20.&#13;
19. Whatmore RW. Nanotechnology--what is it? Should we be worried? Occup Med (Lond) 2006;56:295-9.&#13;
20. Kassem LM, Ibrahim NA, Farhana SA. Nanoparticle therapy is a promising approach in the management and prevention of many diseases: Does it help in curing Alzheimer disease? J Nanotechnol 2020;2020:8147080.&#13;
21. Raval N, Maheshwari R, Kalyane D, Youngren-Ortiz SR, Chougule MB, Tekade RK. Chapter 10-importance of physicochemical characterization of nanoparticles in pharmaceutical product development. In: Advances in Pharmaceutical Product Development and Research, Basic Fundamentals of Drug Delivery. Cambridge, Massachusetts: Academic Press; 2019. p. 369-400.&#13;
22. Teleanu DM, Negut I, Grumezescu V, Grumezescu AM, Teleanu RI. Nanomaterials for drug delivery to the central nervous system. Nanomaterials (Basel) 2019;9:371.&#13;
23. Saraiva C, Praand;ccedil;a C, Ferreira R, Santos T, Ferreira L, J Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 2016;235:34-47.&#13;
24. Ahmad J, Akhter S, Rizwanullah M, Khan MA, Pigeon L, Addo RT, et al. Nanotechnology based theranostic approaches in Alzheimer’s disease&#13;
management: Current status and future perspective. Curr Alzheimer Res 2017;14:1164-81.&#13;
25. Wei H, Bruns OT, Kaul MG, Hansen EC, Barch M, Wi?niowska A, et al. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents. Proc Natl Acad Sci U S A 2017;114:2325-30.&#13;
26. Nanoemulsions Encyclopedia. Available from: https:// www.encyclopedia.pub/6784 [Last accessed on 2021].&#13;
27. Dendrimer-an Overview. Science Direct Topics. Available from: https://www.sciencedirect.com/topics/chemistry/ dendrimer [Last accessed on 2021].&#13;
28. Wang P, Zheng X, Guo Q, Yang P, Pang X, Qian K, et al. Systemic delivery of BACE1 siRNA through neurontargeted nanocomplexes for treatment of Alzheimer’s disease. J Control Release 2018;279:220-33.&#13;
29. Aliev G, Ashraf GM, Tarasov VV, Chubarev VN, Leszek J, Gasiorowski K, et al. Alzheimer’s disease-future therapy based on Dendrimers. Curr Neuropharmacol&#13;
30. Ordand;oacute;and;ntilde;ez-Gutiand;eacute;rrez L, Wandosell F. Nanoliposomes as a therapeutic tool for Alzheimer’s disease. Front Synaptic Neurosci 2020;12:20.&#13;
31. Gao N, Sun H, Dong K, Ren J, Qu X. Gold-nanoparticle based multifunctional amyloid-and;beta; inhibitor against Alzheimer’s disease. Chemistry 2015;21:829-35.&#13;
32. Sivanesan S, Rajeshkumar S. Gold nanoparticles in diagnosis and treatment of Alzheimer’s disease. In: Nanobiotechnology in Neurodegenerative Diseases. Cham: Springer; 2019. p. 289-306.&#13;
33. Xu Y, Zhao M, Zhou D, Zheng T, Zhang H. The application of multifunctional nanomaterials in Alzheimer’s disease: A potential theranostics strategy. Biomed Pharmacother 2021;137:111360.&#13;
34. Inbaraj BS, Chen BH. An overview on recent in vivo biological application of cerium oxide nanoparticles. Asian J Pharm Sci 2020;15:558-75.&#13;
35. Cerium Oxide Nanoparticle-an Overview. Science Direct Topics. Available from: https://www.sciencedirect.com/ topics/pharmacology-toxicology-and-pharmaceuticalscience/cerium-oxide-nanoparticle [Last accessed on 2021].&#13;
36. Henna TK, Pramod K. Graphene quantum dots redefine nanobiomedicine. Mater Sci Eng C Mater Biol Appl 2020;110:110651.&#13;
37. Ghosh S, Sachdeva B, Sachdeva P, Chaudhary V, Rani GM, Sinha JK. Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer’s disease. Carbon Lett 2022;32:1381-94</References>